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Background: Poor adherence to antipsychotic medication is a widespread problem, and the largest predictor of
relapse in patients with psychosis. Electronic reminders are increasingly used to improve medication adherence for
a variety of medical conditions, but have received little attention in the context of psychotic disorders. We aimed to
explore the feasibility and acceptability of including short message service (SMS) medication reminders in the
aftercare plan of service users discharged from inpatient care on maintenance antipsychotic medication.
Methods: We conducted a cross-sectional, trust-wide survey in the inpatient units of the Oxleas National Health
Service (NHS) Foundation Trust in the UK between June 29 and August 3, 2012. Using a self-report questionnaire
and the Drug Attitude Inventory, we examined inpatient attitudes towards antipsychotic drugs, past adherence
to antipsychotic medication, frequency of mobile phone ownership, and interest in receiving SMS medication
reminders upon discharge from the ward. Predictors of a patient’s interest in receiving electronic reminders were
examined using simple logistic regression models.
Results: Of 273 inpatients, 85 met eligibility criteria for the survey, showed decisional capacity, and agreed to
participate. Of the 85 respondents, over a third (31-35%) admitted to have forgotten to take/collect their
antipsychotic medication in the past, and approximately half (49%) to have intentionally skipped their
antipsychotics or taken a smaller dose than prescribed. Male patients (55%), those with negative attitudes towards
antipsychotics (40%), and those unsatisfied with the information they received on medication (35%) were
approximately 3 to 4 times more likely to report past intentional poor adherence. The large majority of respondents
(80-82%) reported having a mobile phone and knowing how to use SMS, and a smaller majority (59%) expressed
an interest in receiving SMS medication reminders after discharge. No variable predicted a patient’s interest in
receiving electronic reminders of antipsychotics.
Conclusions: Automatic SMS reminders of antipsychotic medication were acceptable to the majority of the survey
respondents as an optional service offered upon discharge from inpatient care. Automatic electronic reminders
deserve further investigation as a flexible, minimally invasive, cost-effective and broadly applicable tool that can
potentially improve antipsychotic adherence and clinical outcomes.
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Psychoses are severe disorders of thinking, perception
and emotions, which affect 50 per 100,000 individuals in
the UK every year [1]. Episodes of psychosis, together
with dementia and quadriplegia, are ranked in the highest
disability “class” by health professionals [2], and occur
in the context of several psychiatric disorders - mainly
schizophrenia, but also depression, bipolar illness and sub-
stance abuse disorders [3]. The substantial cost of schizo-
phrenia to UK society, estimated to approach £7 billion in
2004/05 [4], is largely accounted for by inpatient stays,
pharmacological and psychosocial interventions and loss
of financial opportunity [5].
Much of the burden psychotic disorders place on pa-
tients, carers, the health service and society, is the result
of relapses, which typically disrupt psychosocial and vo-
cational adjustment, and increase the risk of hospita-
lisation and suicide [6]. Antipsychotic medication, the
first-line treatment for psychosis [7], can be highly ef-
fective in preventing relapse [8], particularly after the
first episode [9]. Unfortunately, a substantial proportion
of patients (35-75%) discontinue their antipsychotic me-
dication within 1-2 years of follow-up, a further sub-
group are only partially adherent, and only a minority
(8-33%) are fully adherent to treatment [10-14]. Poor
adherence to antipsychotic medication is the largest
predictor of relapse in patients with psychosis [15].
Treatment discontinuation and poor adherence to an-
tipsychotics can result from several factors, including
lack of insight, concern about stigma, persistent symp-
toms or side effects, lack of routines, cognitive deficits,
poor therapeutic alliance, and lack of family support [16].
Negative attitudes towards antipsychotic medication are
the strongest predictor of treatment discontinuation, par-
ticularly in first-episode schizophrenia [17-21]. In general,
while negative attitudes usually contribute to a patient’s
conscious choice to skip or discontinue medication in
various medical contexts, time-keeping difficulties and
forgetfulness can play a critical role in unintentional
non-adherence [22,23].
Electronic reminders (automatically sent reminders
without personal contact between the healthcare provi-
der and the patient) are now increasingly used to im-
prove adherence to long-term treatment for a variety of
medical conditions [24]. The short-term effectiveness of
these paradigms, especially short message service (SMS)
reminders, is receiving increasing support, although their
long-term effects are yet to be established [24]. To date, 3
studies have examined the value of SMS interventions in
improving medication adherence in patients with psy-
chosis [25-27], and 2 reported positive findings [26,27].
As these studies were conducted in Spain, the US and
the Netherlands, it is unclear how cross-national differ-
ences in attitudes towards mobile technology or e-healthapplications, in demographic factors, or in infrastructure
capacity may influence the applicability of the respective
findings to the UK.
Several questions are worth exploring before piloting
electronic systems of antipsychotic medication remin-
ders for users of psychiatric services in the UK. For
example, what percentage of patients who are regularly
prescribed oral antipsychotics own a mobile phone, know
how to use SMS and are willing to receive medication
reminders? What percentage of this population report
forgetting to take their antipsychotic medication in the
community (and hence would most likely benefit from
electronic reminders)? What factors predict a patient’s
willingness to receive SMS antipsychotic medication
reminders?
We report on a Trust-Wide survey conducted in the
inpatient units of the Oxleas National Health Service
(NHS) Foundation Trust, which addressed the above
questions. The general aim of the study was to explore
the feasibility and acceptability of including SMS medi-
cation reminders in the standard aftercare plan of users




Over the survey period (June 29-August 3, 2012) a to-
tal of 273 adult patients received psychiatric inpatient
services at the Oxleas National Health Service (NHS)
Foundation Trust (in the Greenwich, Bromley and Bexley
inpatient units, comprising eight acute wards). Of these,
108 patients met general eligibility criteria for the study
(see below) and were invited to participate, 86 agreed to
take part, and 85 demonstrated decisional capacity, mak-
ing up the final study sample. All participants met the fol-
lowing inclusion criteria: 1) They were receiving regular
doses of oral antipsychotic medication, which would also
be prescribed upon discharge, 2) they demonstrated psy-
chological, social and occupational functioning equivalent
to a score of >50 in the Global Assessment of Functioning
(GAF) Scale [28] (indicating less than severe difficulties),
3) they were able to read and understand English (accord-
ing to nursing staff and self-report), 4) they demonstrated
decisional capacity based on the administration of the
University of California, San Diego Brief Assessment of
Capacity to Consent (UBACC) scale [29], and 5) they pro-
vided written informed consent for the study. Patients
with diagnoses of learning disabilities and those who
would be discharged into 24-hour care residential homes
were excluded, as these groups were likely to rely on
caregivers for receiving their medication, and were
thus unlikely to benefit from text message reminders.
We also excluded patients considered to be unsuitable
for the study by the ward staff (e.g. those with offensive,
Bogart et al. BMC Psychiatry 2014, 14:15 Page 3 of 9
http://www.biomedcentral.com/1471-244X/14/15aggressive or inappropriate conduct). The patients’ eligi-
bility for the study was established based on a variety of
sources, including drug charts, schedules routinely ad-
ministered in the clinical setting (GAF) [28], the stu-
dy questionnaires (see below), the electronic clinical
records system of the Oxleas NHS Foundation Trust
(RiO), and consultations with mental health practitioners
in charge of the patients’ care. The process of deriving the
study sample is summarised in Figure 1.
The study was approved by the Oxleas Research and
Development office, which advised that the investigation
was a service evaluation and did not require ethical
approval.
Assessments
The University of California, San Diego Brief Assessment
of Capacity to consent (UBACC) scale [29] was used to as-
sess the prospective participants’ level of comprehension
of the study, and capacity to consent. The UBACC is a
flexible instrument with brief administration time (ap-
proximately 5 minutes), which can be tailored to the spe-
cific research protocol of each study [29].
A 10-item self-report questionnaire was used to exam-
ine 1) the feasibility and acceptability of using SMS re-
minders of antipsychotic medication in patients with
severe mental illness after they are discharged from an
acute psychiatric unit, and 2) patterns of past adherence
to antipsychotic medication. The instrument (items shown
in Table 1), was adapted from a survey of adherence to
antidepressant medications in community settings [30].
As a potential predictor of medication adherence and
of the interest in receiving text-message reminders ofFigure 1 Process of sample derivation.antipsychotic medication, attitudes to antipsychotic treat-
ment were assessed using the short form of the Drug
Attitude Inventory (DAI-10) [31]. This is a simple and
easy-to-use self-report instrument with good psychomet-
ric properties, which assesses a unique clinical dimension
relevant to non-adherence [17]. A positive sum of scores
indicates a positive subjective response to medication and
a negative sum of scores indicates a negative subjective
response.
Data analysis
The data were analysed using IBM SPSS Statistics 20
and STATA 11. Descriptive statistics were used to ex-
plore the frequency of the following characteristics in
the sample: Mobile phone ownership, knowing how to
use text-messaging, interest in receiving automatic medi-
cation reminders after hospital discharge, poor past adher-
ence to medication, and positive/negative drug attitudes.
Potential predictors of a patient’s interest in receiving text
message reminders of antipsychotic medication were ex-
plored in a series of simple logistic regression models. The
following predictors were analysed: Individual demo-
graphic and clinical characteristics (as shown in Table 2),
mobile phone ownership, past intentional or unintentional
non-adherence to antipsychotic medication, satisfaction
with the medication information received by the health
services, and attitudes towards antipsychotic treatment.
Results
The demographic and clinical characteristics of the ana-
lytic sample (n = 85) are shown in Table 2. A summary of
the survey findings is presented in Table 1. The results of





1) Do you have a mobile telephone? 70 82
2) Can you use the text messaging services? 68 80
Before coming to this ward:
3) Were you ever prescribed antipsychotic medications (if NO, go to question 8) 74 87
4) Did you ever forget to collect your antipsychotic prescription?1 26 35
5) Did you ever forget to take your medication?1 23 31
6) Did you ever intentionally skip your antipsychotic medication or take less than the prescribed dose?1 (if NO, go to question 8) 36 49
7) If YES to question 6, what were your reasons (TICK all that apply)2:
i. I did not like the side effects 18 50
ii. I thought that a smaller dose would do fine 15 42
iii. I was trying to cut down on the number of tablets I took 14 39
iv. I did not think they actually worked that well 14 39
v. I felt better without them 10 28
vi. I was not convinced I had an illness 14 39
vii. I did not have symptoms at the time 18 50
vii. Other (please explain):
8) Do you feel you receive enough information about antipsychotic medication? 55 65
After you have been discharged:
9) Would you be interested in receiving text message reminders from the Trust to help you to remember to take your
antipsychotic medications?
50 59
1The percentages of respondents who answered YES to questions 4, 5, 6 refer to the sub-sample of 74 respondents who answered YES to question 3.
2The percentages of respondents who answered YES to items i - vii of question 7 refer to the sub-sample of 36 respondents who answered YES to question 6.
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of a patient’s willingness to receive electronic reminders
are shown in Table 3.
Of the 85 participants, 82% reported having a mobile
phone. Knowing how to use SMS was reported by 80%
of the total analytic sample and 90% of those who had a
mobile phone. Similar percentages in the total analytic
sample (59%) and in the subgroup of mobile-phone
owners (57%) expressed an interest in receiving SMS
medication reminders after being discharged from the
ward (Table 1).
Of the 74 inpatients who reported having been pre-
scribed antipsychotic agents in the past, just over a
third (31-35%) reported experiences of unintentional
non-adherence, and approximately half (49%) admit-
ted to have intentionally skipped their antipsychotic
medication or taken a smaller dose than prescribed.
The most commonly stated reasons for intentional non-
adherence were ‘side effects’ (50%), ‘not having symp-
toms at the time’ (50%), and ‘thinking that a smaller
dose would do fine’ (42%) (Table 1). Of the subgroup of
unintentional non-adherers, 56% expressed an interest
in receiving SMS medication reminders after being dis-
charged from the ward.No demographic or clinical variable predicted interest
in receiving SMS medication reminders, although age
showed a trend towards significance (Table 3). Mobile
phone ownership, past adherence to antipsychotic medi-
cation, satisfaction with medication information, and at-
titudes towards antipsychotic treatment also failed to
predict interest in receiving SMS medication reminders
(Table 3).
Of the 85 participants, those with negative attitudes
towards antipsychotic medication (40%), those who per-
ceived the information they received on treatment as
insufficient (35%) and males (55%) were approximately 3
to 4 times more likely to report having intentionally
skipped their antipsychotic medication in the past (nega-
tive attitudes: OR = 4.00, 95% CI 1.50 to 10.66, p < 0.01;
insufficient information: OR = 2.79, 95% CI 1.07 to 7.29,
p < 0.05; male gender: OR = 2.95, 95% CI 1.14 to 7.63,
p < 0.05). None of the three variables was a significant
predictor of unintentional non-adherence (OR = 0.75-
1.49, p > 0.10).
Discussion
Our trust-wide survey at the Oxleas NHS Foundation
Trust demonstrated that approximately 60% of in-patients
Table 2 Demographic and clinical characteristics of
participants














Working or studying 15 18
Not working 65 76
Marital status
Has partner 25 29












1The cumulative percentages for ‘Ethnicity’ and ‘Employment Status’ are 98%
and 94%, respectively, due to missing values.
2Daily dosage of prescribed antipsychotic (% of patients): 0.5-30 mg (47%),
50-250 mg (8%), 300-800 mg (30%).
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ness to benefit from SMS-based interventions for increas-
ing medication adherence. More than three quarters of
the respondents reported to own a mobile phone (82%)
and be able to use SMS (80%), while 59% expressed an
interest in receiving electronic prompts from the Trust
to remind them to take their oral antipsychotics after
discharge.
In line with previous findings [10-14], the prevalence
of self-reported poor adherence to antipsychotic medi-
cation among the survey respondents was substantial.
Over a third (31-35%) reported to have previously for-
gotten to take or collect their antipsychotic medication,
and approximately half (49%) to have intentionally
skipped, or taken less than, the prescribed dose.There were no demographic or clinical characteristics
that predicted a patient’s interest in receiving electronic
medication reminders. Similarly, owning a mobile phone,
previous levels and patterns of adherence to medication,
level of satisfaction with the medication information re-
ceived from the services, and attitudes towards anti-
psychotic treatment were not significantly associated with
a patient’s interest in receiving reminders.
Our findings suggest that, regardless of demographic
and diagnostic characteristics, attitudes towards medi-
cation, and patterns of past adherence, the majority of
patients with psychotic disorders are likely to respond
positively to an offer of electronic reminders of antipsy-
chotic medication as an optional care provision after dis-
charge from an inpatient ward. Therefore, SMS prompts
of antipsychotic medication show promise as a low-cost
intervention, which could potentially result in large-scale
clinical and economic benefits through intervening in the
adverse pathway from medication non-adherence to re-
lapse to inpatient admission [7-9,15]. Furthermore, the
prominence of both intentional and involuntary factors in
the aetiology of non-adherence, suggests that persona-
lised, needs-based approaches, which variably incorp-
orate reminders and/or motivational content, might be
optimally suited for maximising the benefits of SMS-
based interventions.
Male gender, negative attitudes towards antipsychotic
medication and lack of satisfaction with the information
received on medication were significantly associated with
an approximately 3- to 4- fold increase in risk for in-
tentional non-adherence in the present study. These fin-
dings suggest a critical need for encouraging positive
attitudes towards antipsychotic medication, especially
among male patients. In addition, it is important for
patients to receive sufficient information about anti-
psychotic treatment. Well-informed patients are more
likely to have insight into their illness, recognise the im-
portance of treatment adherence [17,32-34], and develop
therapeutic alliance with service providers.
Adopting SMS technologies is increasingly common
and affordable in the UK. National figures show a rapid
increase in mobile phone ownership from approximately
79% in 2010 to 91% in 2011 [35,36]. This trend is also
present among patients with severe mental illness. Com-
pared to the prevalence of mobile phone ownership in
the present study (82%), only 62% of psychiatric inpa-
tients in the Oxleas Trust were reported to own a mo-
bile phone in an earlier survey by our group [37]. In
addition to the dramatic increase in mobile device use
and infrastructure capacity in the UK, these figures sug-
gest that the prevalence of mobile phone ownership
among patients with severe mental illness is lower than
in the general population. This observation reflects global
trends. For example, a 2011 survey of 1,592 individuals
Table 3 Predictors of interest in receiving text message reminders of antipsychotic medication
LR
chi2




Male 0.72 0.30 1.73
Age 5.59 0.06
18–35 1.00
36–50 0.45 0.18 1.16
51–67 0.18 0.03 1.05
Ethnicity 3.62 0.16
White 1.00
Black 0.26 0.06 1.12
Other 0.92 0.29 2.93
Employment 0.01 0.93
Working or studying 1.00
Not working 0.95 0.30 2.99
Marital Status 0.09 0.76
Has partner 1.00
No partner 1.17 0.44 3.12
Diagnosis (disorder) 1.19 0.76
Nonaffective 1.00
Affective 1.10 0.27 4.55
Substance induced/organic 1.60 0.3 8.49
Other 0.60 0.12 2.97
Type of antipsychotic agent 0.62 0.96
Risperidone 1.00
Quetiapine 1.31 0.40 4.32
Clozapine 0.80 0.15 4.24
Olanzapine 1.12 0.33 3.85
Other 1.60 0.23 11.08
Do you have a mobile telephone? 0.47 0.50
No 1.00
Yes 0.67 0.21 2.15
Did you ever forget to take your medication? 0.06 0.80
No 1.00
Yes 0.88 0.33 2.38
Did you ever intentionally skip … or take less than the prescribed dose? 0.05 0.83
No 1.00
Yes 1.11 0.44 2.79
Do you feel you receive enough information … medication? 0.39 0.53
No 1.00
Yes 0.74 0.30 1.87
Drug Attitutes (DAI score) 0.20 0.65
Positive 1.00
Negative 0.82 0.34 1.97
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72% prevalence of mobile device ownership among people
with SMI, which was approximately 12% lower than found
in the general adult population [38]. The most frequently
reported barrier to mobile device ownership was cost [38],
reflecting the well-established relationship between pov-
erty and severe mental illness [39]. However, less than a
quarter of mobile device non-users in the U.S. sample in-
dicated a lack of interest, and even fewer said they did not
know how to use a mobile device [38], suggesting a nar-
row influence of such barriers on patients with severe
mental illness.
Our findings add to a growing body of evidence
highlighting the value of treatment-supporting technolo-
gies in improving medication adherence and other clinical
outcomes in severe mental illness, including internet-
based interventions [40], short-message-service technolo-
gies [24,41] and electronic diaries [42]. It is important to
emphasize that any recommendations for addressing me-
dication non-adherence in the context of psychotic dis-
orders should acknowledge the extensive evidence base
demonstrating that a combination of adjunctive educa-
tional, behavioural, and affective strategies is likely to
prove more effective than any intervention used in iso-
lation [43]. It is further recommended that the effect
of interventions on medication adherence be considered
alongside other important outcome parameters, such as
quality of life [44].
Our study findings should be considered in the con-
text of potential imitations. As our aim was to establish
the acceptability of electronic medication reminders at
the point of discharge from inpatient care, our survey fo-
cused on psychiatric inpatients. However, individuals ad-
mitted to a mental health unit are typically very unwell
[45]. We addressed this inherent limitation by introdu-
cing a variety of inclusion and exclusion criteria in our
selection strategy, including functional and decisional
capacity in our study inclusion criteria, and learning dis-
abilities, discharge into 24-hour residential care, and
clinician-judged ‘unsuitability’ for the study (offensive,
aggressive or inappropriate conduct) in our exclusion
criteria. This approach may have introduced bias into
the study sample, and reduced the relevance and applic-
ability of our findings to patients at the lower end of the
functional spectrum (who may differ from the study par-
ticipants during both acute and sub-acute phases). In
addition, we limited our inclusion strategy to patients
who can read and understand English. This selection strat-
egy reduced the generalizability of our findings to patients
with a migrant status. It would thus be informative to
compare the present findings with those of a future survey
of psychiatric outpatients on regular antipsychotic pre-
scriptions. Other potential limitations of the study include
the unmeasured social desirability effect, which may haveinflated the percentage of participants responding affirma-
tively to some survey items; the assumption that the sur-
vey respondents knew the answers to all the questions
(however, it is possible that some participants were not
able to accurately recall, and/or correctly classify as ‘anti-
psychotics’, some of the drugs they were prescribed in the
past); the relatively narrow range of items included in the
core questionnaire, which excluded potentially interesting
questions about the use of SMS in the target population
(for example, how extensively patients used SMS; for what
purposes; what kinds of messages they might like to re-
ceive, how the reminders could best address their needs);
the relatively small size of the survey sample, which may
have failed to adequately capture the range and propor-
tions of the different psychotic disorders in the clinical
population; and the limitation of conducting the survey at
a single institution, potentially reducing the generaliz-
ability of findings. Finally, the prevalence of self-reported
intentional and unintentional non-adherence was a sec-
ondary focus of the present survey, but self-reports have
been criticised for under-estimating the true extent of
poor adherence [46], and, therefore, ought to be inter-
preted with caution.
Conclusion
Our findings suggest that an optional service of automatic
SMS reminders of antipsychotic medication, offered upon
discharge from an inpatient unit, is acceptable to the ma-
jority of psychiatric patients who are prescribed oral anti-
psychotic medication, regardless of their demographic and
diagnostic characteristics, attitudes towards medication
and levels of past adherence. The prospect of a flexible,
minimally invasive, cost-effective and broadly applicable
tool that can potentially improve adherence to anti-
psychotic treatment is exciting. The results of the present
survey should be extended by future pilot and definitive
trials investigating how the reminder service could work
in practice, and if it improves medication adherence and
clinical outcomes. Our study findings further suggest that
improving adherence to antipsychotic treatment should
critically incorporate strategies for improving attitudes to-
wards, and dissemination of information on, antipsychotic
medication.
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